Assessing lung inflammation using PET imaging
Official title: PET Imaging CCR2 in Lung Inflammation
Run by Washington University School of Medicine · NCT03492762 · Data updated 2026-11-12
This study is testing a new imaging tool to see if it can help track inflammation in the lungs of people with fibrotic lung diseases.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 21 Years and up |
| Sex | All |
| Enrollment | 110 (estimated) |
| Sponsor | Washington University School of Medicine Academic / other |
| Locations | 1 site (St Louis, Missouri) |
| Status | Recruiting |
| Started | February 27, 2018 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | May 1, 2026 |
| Trial ID | NCT03492762 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 21 and older with a history of smoking and diagnosed with fibrotic lung diseases.
✕Probably not a fit
Patients with significant comorbidities affecting lung function or those currently enrolled in other conflicting studies may not benefit from this trial.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot clinical trial aims to evaluate the distribution of a PET imaging radiotracer, Cu-DOTA-ECL1i, in patients with fibrotic lung diseases. The study will involve 60 patients with interstitial lung disease (ILD) and 5 healthy volunteers as controls, all undergoing dynamic PET/CT scans to characterize the uptake of the radiotracer in the lungs. Additionally, sub-studies will assess the reproducibility of the scans and the correlation between imaging results and inflammatory cell distribution in lung tissue. The overall goal is to determine the potential of this radiotracer to track inflammatory cells in lung diseases.
Why it matters
Potential benefit: If successful, this study could provide a new imaging tool to better understand and monitor lung inflammation in patients with fibrotic lung diseases.
How similar studies have gone: While this approach is innovative, similar studies using PET imaging for tracking inflammation have shown promise, indicating potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men or women 21 years of age or older who have never smoked or current smokers who smoked at least 10 cigarettes per day (1/2 pack) and have smoked at least 100 cigarettes (5 packs) over the past month. * Screening FEV1 and FVC \> 80% of predicted * Capable of lying still and supine within the PET/CT and PET/MR scanner for \~1 hour and follow instructions for breathing protocol during the CT portion * No illicit drug use or other inhaled drug use (including pharmacologic agents, recreational agents, or illicit drugs) within the past year * No known history of cardiac, pulmonary, hepatic or renal disease or diabetes * No history of claustrophobia or other preventing condition that has previously or would interfere with completion of protocol specified imaging sessions * Able to comprehend and willing to follow instructions for the study procedures as called for by the protocol * BMI ≤ 35 Exclusion Criteria: * Currently enrolled in another study using an investigational drug * Pregnancy (confirmed by urine pregnancy test) * Active symptoms or history of cardiac, pulmonary, hepatic or renal disease or diabetes * Currently taking any prescription medications * Presence of an implanted device that is incompatible with CT or MRI scanning * Creatinine \> 1.30 mg/dL, AST \> 50 Units/L, ALT \> 55 Units/L, or total bilirubin \> 1.2 mg/dL
Where it's running
-
Washington University School of Medicine
St Louis, Missouri, United States Recruiting
Study contacts
- Principal investigator: Steven Brody, MD — Washington University School of Medicine
- Study coordinator: Steven Brody, MD
- Email: brodys@wustl.edu
- Phone: 314-362-8969
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Trop2- and EpCAM-targeted PET/CT to help distinguish non-small cell lung cancer
This project will test whether PET/CT scans that target Trop2 and EpCAM can show protein expression in tumors of people with suspected non-small cell lung cancer.
-
Using cough samples to analyze lung health
This study is testing whether cough samples can help us find signs of lung diseases by comparing them to samples taken from healthy people and smokers.
-
How age affects germinal center responses after flu and rabies vaccines
Researchers will test how the immune system responds to flu and rabies vaccines in younger adults (18–40) and older adults (65+).
-
Cognitive Tasks and Models in a Large Online Sample
This study tests cognitive tasks and computational models in a large online group to see if these tools can help predict symptoms like hallucinations and delusions in the general population.
-
Can seven tasks help distinguish schizophrenia and schizoaffective disorder from healthy people
The study tests seven cognitive tasks to see if they can tell apart people with schizophrenia or schizoaffective disorder from healthy adults and predict symptoms like hallucinations and delusions.
-
Online perioperative education to support head and neck cancer patients and their caregivers
This trial tests a digital education program called CareOrbit to see if it improves understanding, satisfaction, and outcomes for adults with head and neck cancer undergoing reconstructive surgery or laryngectomy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.